Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from extravascular spaces (e.g., brain, eyes) into the intravascular compartment and enhancing water excretion by the kidneys. Dextrose provides caloric supplementation, and sodium chloride provides electrolytes to maintain tonicity.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Reduction of intracranial pressure (FDA-approved for cerebral edema),Reduction of intraocular pressure in acute glaucoma,Promotion of diuresis in drug overdose (e.g., barbiturates, salicylates),Osmotic diuresis in acute renal failure prevention (e.g., during cardiovascular surgery),Adjuvant in urology for bladder irrigation (off-label),Prevention of acute kidney injury in rhabdomyolysis (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous infusion. For osmotic diuresis: 50-100 g (1000-2000 m L of this solution) over 1-2 hours, total dose not exceeding 200 g/day. For reduction of intracranial pressure: 1.5-2 g/kg as a 20-25% solution given IV over 30-60 minutes. This 5% solution is not typically used for ICP reduction due to dilution.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Mannitol: 0.25–1.5 hours (approximately 15–90 minutes); prolonged in renal impairment. Dextrose: <30 minutes (endogenous regulation).
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Mannitol is not significantly metabolized; it is freely filtered by the glomeruli and excreted unchanged in urine. Dextrose is metabolized via glycolysis and oxidative phosphorylation. Sodium chloride dissociates into ions that are handled by renal tubular transport.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: >90% mannitol excreted unchanged in urine; dextrose is fully reabsorbed or metabolized; sodium chloride is handled by renal tubules.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Mannitol: 0% (not bound); dextrose: negligible; sodium: minimal.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Mannitol: ~0.3–0.7 L/kg; distributes primarily in extracellular fluid; does not cross cell membranes significantly.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% for all components.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Contraindicated in anuria due to severe renal disease or severe renal impairment (GFR <10 m L/min). Caution in mild to moderate impairment; monitor serum osmolality and electrolytes. No specific GFR-based dose adjustment established.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific adjustment for Child-Pugh class. Caution in severe hepatic impairment due to risk of fluid overload and electrolyte disturbances.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
For osmotic diuresis: 2 g/kg IV over 1-2 hours as a 15-20% solution. For cerebral edema: 1-2 g/kg IV over 30-60 minutes as a 20-25% solution. Not typically using this 5% formulation for these indications.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution due to age-related decline in renal function. Monitor renal function, fluid balance, and electrolytes. Initiate at low end of dosing range.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
May cause circulatory overload, pulmonary edema, or congestive heart failure in patients with compromised cardiac function. Monitor serum electrolytes, osmolality, and renal function. Use with caution in patients with anuria, severe renal impairment, or active intracranial bleeding (risk of expansion). Avoid extravasation (can cause tissue necrosis). Rapid administration may cause headache, nausea, or blurred vision.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Anuria (due to severe renal disease), pulmonary edema (due to fluid overload), active intracranial bleeding (unless during craniotomy), severe dehydration, established acute tubular necrosis (use may worsen), hypersensitivity to any component.
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions. However, avoid high-sodium foods to prevent exacerbation of hypernatremia.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Pregnancy Category C. Mannitol and dextrose combinations are generally considered low risk for teratogenicity. Mannitol is an osmotic diuretic that does not cross the placenta significantly at therapeutic doses. Dextrose is a normal constituent of maternal and fetal blood; however, hyperglycemia from dextrose infusion may be associated with fetal hyperinsulinism and macrosomia if maternal glucose is poorly controlled. No specific teratogenic effects have been reported for this combination. Benefit-risk assessment is required.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Mannitol and dextrose are endogenous substances or metabolites. Mannitol is excreted into breast milk in small amounts (M/P ratio unknown but likely low due to high molecular weight). Dextrose is a normal milk component. I. V. administration may raise maternal blood glucose, but effects on infant are minimal at therapeutic doses. Caution in lactation due to potential for maternal hyperglycemia.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Due to increased plasma volume (50% increase) and glomerular filtration rate (50-60% increase) in pregnancy, clearance of mannitol and dextrose may be enhanced. Monitor serum osmolarity and electrolytes; adjust infusion rate to avoid hyperosmolarity or fluid overload. No specific dose reduction required but careful titration is recommended. Blood glucose monitoring is essential to avoid maternal hyperglycemia.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Monitor serum sodium and osmolality closely due to risk of hypernatremia and hyperosmolality; contraindicated in anuria, severe pulmonary edema, and intracranial hemorrhage. Use with caution in patients with renal impairment or congestive heart failure.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Report any swelling, shortness of breath, or rapid weight gain.,Do not consume additional salt in diet while receiving this infusion.,Inform healthcare provider if you have kidney problems or heart failure.,This medication may cause increased urination; keep track of fluid intake and output.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is a Electrolyte that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from extravascular spaces (e.g., brain, eyes) into the intravascular compartment and enhancing water excretion by the kidneys. Dextrose provides caloric supplementation, and sodium chloride provides electrolytes to maintain tonicity.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is: Intravenous infusion. For osmotic diuresis: 50-100 g (1000-2000 m L of this solution) over 1-2 hours, total dose not exceeding 200 g/day. For reduction of intracranial pressure: 1.5-2 g/kg as a 20-25% solution given IV over 30-60 minutes. This 5% solution is not typically used for ICP reduction due to dilution.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% is classified as Category A/B. Pregnancy Category C. Mannitol and dextrose combinations are generally considered low risk for teratogenicity. Mannitol is an osmotic diuretic that does not cross the placenta sign. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.